- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04026178
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Janet Boylan
- Phone Number: +353 1 518 0200
- Email: janet.boylan@amrytpharma.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Univ. Alabama-Birmingham
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Ohio
-
Columbus, Ohio, United States, 43203
- Ohio State University
-
Columbus, Ohio, United States, 43201
- Endocrinology Research Associates
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Childrens Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, United States, 75390
- University Texas Southwestern INT
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures. If <18 years of age, has a parent or guardian able to read, understand, and sign the Informed Consent Form (ICF) and a Child Assent form, communicate with the Investigator, and understand and comply with protocol requirements. Adolescent patients must also read and understand the Child Assent Form. If the child is too young or unable to read, then the Child Assent form must be explained to the child.
- Female and/or male patients ≥1 years of age.
- Physician-confirmed diagnosis of congenital or acquired generalized lipodystrophy and will begin treatment with MYALEPT for the first time.
- Negative pregnancy test (urine or serum) for female patients of childbearing potential.
- Female patients of childbearing potential must be 1 year postmenopausal, surgically sterile, or be willing to use an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent). In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.
- Male patients must be surgically sterile or be willing to use an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent).
- Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of metreleptin.
Exclusion Criteria:
- Involvement in the planning and/or conduct of the study (applies to both Aegerion staff and/or staff at the study site.)
- Previous treatment with metreleptin.
- Participation in another clinical study with an investigational product during the last 6 months.
- Patients with prior severe hypersensitivity reactions to metreleptin or to any of the product components.
- Known to have tested positive for human immunodeficiency virus, are immunocompromised, or are receiving immunomodulatory drugs.
- Known history of drug or alcohol abuse within 1 year of screening.
Creatinine clearance <30 mL/min using institutional standards:
e.g., calculated using Cockcroft-Gault formula for patients ≥18 years of age; calculated using Schwartz equation for patients <18 years of age.
- For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
- Any condition where, in the opinion of the Investigator, participation in this study may pose a significant risk to the patient or could render the patient unable to successfully complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metreleptin
Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients > 40 kg: 2.5mg Female patients > 40 kg: 5mg
|
Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants who develop anti-metreleptin/leptin antibodies at any timepoint after treatment with metreleptin
Time Frame: Month 36
|
Antibody titers are determined by the ADA Binding Assay
|
Month 36
|
Percentage of participants who develop anti-metreleptin/leptin antibodies with neutralizing activity at any timepoint after treatment with metreleptin
Time Frame: Month 36
|
In vitro neutralizing activity is determined in samples that tested positive for metreleptin/leptin-antibody by the ADA Binding Assay by two methods:
|
Month 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with SAEs, AESIs or adverse events leading to discontinuation
Time Frame: Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Percentage of participants with SAEs, AESIs or adverse events leading to discontinuation
|
Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Percentage of participants with neutralizing or non-neutralizing antibodies who also show one or several of: a. Significant change of HbA1c b. Significant change of triglycerides c. Concomitant SAEs, AESIs or AEs leading to discontinuation
Time Frame: Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Percentage of participants with neutralizing or non-neutralizing anti-metroleptin/leptin antibodies who also show one or several of:
|
Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants who show a significant change in hemoglobin A1c
Time Frame: Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Absolute change of Hemoglobin A1c from baseline level
|
Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Percentage of participants who show a significant change in fasting triglycerides
Time Frame: Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Percentage change of triglycerides from baseline level
|
Baseline and Months 1, 2, 4, 6, 9, 12, 18, 24, 30, 36
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Janet Boylan, Aegerion Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AEGR-734-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Lipodystrophy
-
Regeneron PharmaceuticalsActive, not recruitingGeneralized LipodystrophyUnited States, Peru, Russian Federation, Turkey
-
University of Texas Southwestern Medical CenterCompletedInsulin Resistance | Partial Lipodystrophy | Generalized Lipodystrophy | HypoleptinemiaUnited States
-
Regeneron PharmaceuticalsAvailablePartial Lipodystrophy | Generalized Lipodystrophy | Monogenic Obesity Due to LEP or LEPR Loss of Function
-
National Institute of Diabetes and Digestive and...RecruitingDiabetes | Hyperlipidemia | LipodystrophyUnited States
-
University of UlmUniversity of Pisa; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaboratorsRecruitingLipodystrophy Acquired | Lipodystrophy CongenitalAustria, France, Germany, Hungary, Italy, Portugal, Spain, Netherlands, Russian Federation, Slovenia, Switzerland, Turkey, United Kingdom
-
Aegerion Pharmaceuticals, Inc.RecruitingPartial Lipodystrophy | Generalised LipodystrophyUnited States, Germany, Italy
-
University Hospital, LilleRecruitingFamilial Partial Lipodystrophy Type 2France
-
Amryt PharmaRecruitingPartial LipodystrophyUnited States, Canada
-
Mayo ClinicCompleted
-
Escola Superior de Tecnologia da Saúde do PortoCompleted
Clinical Trials on Metreleptin
-
Baylor College of MedicineCompleted
-
National Institute of Diabetes and Digestive and...RecruitingDiabetes | Hyperlipidemia | LipodystrophyUnited States
-
University of MichiganAmryt PharmaActive, not recruitingLipomatosis, Multiple SymmetricalUnited States
-
National Institute of Diabetes and Digestive and...Active, not recruitingDiabetes | Hyperlipidemia | LipodystrophyUnited States
-
Amryt PharmaRecruitingPartial LipodystrophyUnited States, Canada
-
University of MichiganAvailable
-
Northwestern UniversityCompletedCongenital Leptin Deficiency (Disorder)United States
-
University of MichiganCompletedNAFLD | Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
University of Texas Southwestern Medical CenterJuvenile Diabetes Research Foundation; Amylin Pharmaceuticals, LLC.Terminated